Bronchodilator response does not associate with asthma control or symptom burden among patients with poorly controlled asthma
- 1 August 2023
- journal article
- research article
- Published by Elsevier in Respiratory Medicine
- Vol. 218, 107375
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline (5U01HL072968)
- National Institutes of Health
- National Heart, Lung, and Blood Institute (U01 HL080433, U01 HL080450)
- American Lung Association
- AstraZeneca (U01 HL 0088367, U01 HL087987, U54TR001018)
This publication has 38 references indexed in Scilit:
- Asthma Symptom Utility Index: Reliability, validity, responsiveness, and the minimal important difference in adult asthmatic patientsJournal of Allergy and Clinical Immunology, 2012
- Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease studyThorax, 2012
- Lansoprazole for Children With Poorly Controlled Asthma: A Randomized Controlled TrialJAMA, 2012
- The Relationship of the Bronchodilator Response Phenotype to Poor Asthma Control in Children with Normal SpirometryThe Journal of Pediatrics, 2011
- Efficacy of Esomeprazole for Treatment of Poorly Controlled AsthmaNew England Journal of Medicine, 2009
- Argument for changing criteria for bronchodilator responsivenessRespiratory Medicine, 2008
- Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control QuestionnaireRespiratory Medicine, 2006
- Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialistsJournal of Allergy and Clinical Immunology, 2006
- Interpretative strategies for lung function testsEuropean Respiratory Journal, 2005
- Standardisation of spirometryEuropean Respiratory Journal, 2005